Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.35 – $2.59
16% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3M | $16.7M | $32.2M | $7.5M | $10.2M | $7.5M | $5.9M | $17.2M |
| Cost of revenue | $5.5M | $75.2M | $81.5M | $85.7M | $63.6M | $54.9M | $41.1M | $5.1M |
| Gross profit | $11.8M | −$58.5M | −$49.3M | −$78.3M | −$53.4M | −$47.4M | −$35.2M | $12.1M |
| Gross margin | 68.2% | -349.5% | -153.4% | -1049.8% | -522.6% | -632.2% | -595.9% | 70.2% |
| R&D | $65.9M | $59.8M | $56.2M | $53.0M | $32.8M | $27.2M | $25.4M | $34.8M |
| Operating income | −$77.3M | −$80.2M | −$74.9M | −$109.1M | −$80.6M | −$69.3M | −$84.1M | −$62.4M |
| EBITDA | −$74.7M | −$84.5M | −$69.0M | −$84.7M | −$76.6M | −$58.5M | −$56.1M | −$73.7M |
| Net income | −$35.3M | −$89.8M | −$77.9M | −$98.8M | −$91.3M | −$81.9M | −$88.0M | −$102.1M |
| Net margin | -203.5% | -537.0% | -242.4% | -1325.3% | -894.6% | -1091.7% | -1490.3% | -593.9% |
| EPS (diluted) | -0.08 | -0.18 | -0.15 | -0.16 | -0.13 | -0.10 | -0.09 | -0.09 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $123M | $-0.03 | $-0.05–$-0.02 | 1 |
| 2027 | $200M | $0.01 | $0.00–$0.01 | 1 |
| 2028 | $303M | $0.07 | $0.05–$0.11 | 1 |
| 2029 | $619M | $0.21 | $0.15–$0.31 | 1 |
Forward consensus · source: Financial Modeling Prep
MESOBLAST LTD ORD
No one on the platform currently holds MEOBF.
No tracked institution reports a position in MEOBF as of their last filing.
No one on the platform has traded MEOBF yet.
| $1.2B |
| — |
| ONTTFOxford Nanopore Technologies plc | $1.66 | +0.00% | $1.6B | — |
| PHMMFPharma Mar, S.A. | $79.49 | +0.00% | $1.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 223.6× sales vs its 91.8× historical median P/S.
Fair value ≈ $0.64 · price $1.55 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.